This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Human Genome: The Night Watch

Updated with latest price quotes.

NEW YORK ( TheStreet) -- Shares of Human Genome Sciences gained in afterhours action after a Food and Drug Administration advisory panel voted in favor of approval for Benlysta, the company's proposed lupus treatment.

The stock was last quoted at $28.42, up 9.8%, on volume of around 1.6 million, according to Nasdaq.com. Human Genome's partner on the drug, GlaxoSmithKline (GSK - Get Report), was also on the rise, adding 2.5% to $39.50 with more than 160,000 shares changing hands.

TheStreet biotech columnist Adam Feuerstein liveblogged the Human Genome FDA panel event all day Tuesday.


Another gainer in late trades was China Digital TV Holding (STV - Get Report), which leapt nearly 9% to $7.40 on volume of around 30,000 following its fiscal third-quarter report.

The Beijing-based company, which sells digital television smart cards in China, said it earned $10.1 million, or 17 cents a share, in the three months ended Sept. 30 as revenue jumped more than 10% on a sequential basis to $21.1 million. Based on a regular session close at $6.81, China Digital shares were up more than 14% so far in 2010. The company said it shipped 3.95 million smart cards in the latest quarter, up from 3.61 million cards in the second quarter, and 1.96 million in the same period a year earlier.

Meantime, shares of Avanir Pharmaceuticals (AVNR) were slipping to the downside after the company disclosed plans to sell additional common stock.

The Aliso Viejo, Calif.-based drug developer gave investors the heads-up on the offering but not much else. It didn't project how big the proposed sale might be, or when it might happen. Jefferies & Co. is acting as the sole bookrunner on the deal with four other firms, including Canaccord Genuity and Merriman Capital, acting as co-managers.

The stock was last quoted at $4.44, down 4%, on volume of more than 640,000, according to Nasdaq.com. Based on a regular session close of $4.62, the shares are up more than 150% so far in 2010, so it's not particularly surprising the company would opt to pursue a dilutive stock sale.

The bulk of the appreciation has come this month after the company announced regulatory approval of its Nuedexta capsules for the treatment of pseudobulbar affect, a neurological condition that Avanir describes as being "characterized by involuntary, sudden, and frequent episodes of laughing and/or crying."
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
AVNR $16.96 0.00%
GSK $41.21 0.00%
STV $2.45 0.00%
SINA $39.16 0.00%
AAPL $112.92 0.00%

Markets

Chart of I:DJI
DOW 16,654.77 +369.26 2.27%
S&P 500 1,987.66 +47.15 2.43%
NASDAQ 4,812.7080 +115.1720 2.45%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs